Invivyd, Inc. Files 8-K
Ticker: IVVD · Form: 8-K · Filed: Oct 29, 2024 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | 8-K |
| Filed Date | Oct 29, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, corporate-update
TL;DR
Invivyd filed an 8-K on 10/29/24. No specific numbers yet, but it's an update.
AI Summary
Invivyd, Inc. filed an 8-K on October 29, 2024, reporting on its results of operations, other events, and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incorporated in Delaware and headquartered in Waltham, MA. This filing does not contain specific financial figures or details of the 'other events'.
Why It Matters
This 8-K filing indicates that Invivyd, Inc. is providing updates on its operational and financial status, which is crucial for investors to understand the company's current standing.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain information that inherently increases risk, such as negative financial results or significant adverse events.
Key Players & Entities
- Invivyd, Inc. (company) — Registrant
- Adagio Therapeutics, Inc. (company) — Former Company Name
- October 29, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Waltham, MA (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Invivyd, Inc.?
The 8-K filing reports on Invivyd, Inc.'s Results of Operations and Financial Condition, Other Events, and Financial Statements and Exhibits as of October 29, 2024.
When was Invivyd, Inc. formerly known as?
Invivyd, Inc. was formerly known as Adagio Therapeutics, Inc., with a date of name change on November 12, 2020.
Where are Invivyd, Inc.'s principal executive offices located?
Invivyd, Inc.'s principal executive offices are located at 1601 Trapelo Road, Suite 178, Waltham, MA 02451.
What is the state of incorporation for Invivyd, Inc.?
Invivyd, Inc. is incorporated in Delaware.
What is the SEC file number for Invivyd, Inc.?
The SEC file number for Invivyd, Inc. is 001-40703.
Filing Stats: 703 words · 3 min read · ~2 pages · Grade level 12.1 · Accepted 2024-10-29 07:17:03
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar
Filing Documents
- ivvd-20241029.htm (8-K) — 50KB
- ivvd-ex99_1.htm (EX-99.1) — 37KB
- ivvd-ex99_2.htm (EX-99.2) — 44KB
- img59752938_0.jpg (GRAPHIC) — 12KB
- img60676459_0.jpg (GRAPHIC) — 12KB
- img60676459_1.jpg (GRAPHIC) — 34KB
- 0000950170-24-117934.txt ( ) — 354KB
- ivvd-20241029.xsd (EX-101.SCH) — 31KB
- ivvd-20241029_htm.xml (XML) — 5KB
02
Item 2.02. Results of Operations and Financial Condition. On October 29, 2024, Invivyd, Inc. (the "Company") issued a press release entitled "Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability" (the "Press Release"), which included the Company's estimated third quarter 2024 PEMGARDA (pemivibart) net product revenue and estimated cash and cash equivalents as of September 30, 2024. The amounts included in the Press Release are preliminary and are subject to change upon completion of the Company's financial closing procedures for the quarter ended September 30, 2024, and finalization of the unaudited interim condensed consolidated financial statements. The preliminary financial data included in the Press Release has been prepared by, and is the responsibility of, the Company's management. PricewaterhouseCoopers LLP, the Company's independent registered public accounting firm, has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto. Additional information and disclosures would be required for a more complete understanding of the Company's financial position and results of operations as of September 30, 2024. A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 2.02.
01
Item 8.01. Other Events. On October 29, 2024, the Company issued the Press Release, a copy of which is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01. On October 29, 2024, the Company issued a press release entitled "Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA (pemivibart) Provided Substantial Protection From Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants." A copy of the press release is filed herewith as Exhibit 99.2 and is incorporated by reference in this Item 8.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 29, 2024 99.2 Press Release, dated October 29, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) MACROBUTTON DocID
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: October 29, 2024 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary MACROBUTTON DocID